Jack Barber Email & Phone Number

San Diego, Ca

• Four semesters as an instructor at Southwestern Community College, teaching general (Chem 100), analytical (Chem 250), and organic and biological chemistry (Chem 110). • Prior to that an independent chemistry and biology tutor of individual high school and college undergraduate students.

Los Angeles, California

SUMMARY: As an officer of this public biopharmaceutical company, was a major contributor rebuilding the company from its restart in mid-2003. Helped increase company market capitalization from $40M at the time I joined in July 2004 to approximately $140M when I left the company in December 2009.CHIEF SCIENTIFIC OFFICER AND SENIOR VICE PRESIDENT, DRUG DEVELOPMENT• In charge of overall discovery, preclinical, and clinical research of small molecule drugs for cancer, neurodegenerative diseases, Stroke, and Diabetic complications, including specific therapies for diabetic ulcers and peripheral neuropathy)• Responsible for building a discovery research laboratory from site identification and negotiation of the lease to a fully operational laboratory a scientific staff of 9 chemists, 9 biologists, and 4 clinical and regulatory professionals. Accomplishments include multiple scientific publications and patent applications• Responsible for scientific and strategic evaluation of M&A and in-licensing opportunities, including the October, 2004 acquisition of the clinical and intellectual property assets of Biorex Research and Development Company including three clinical stage oral drug candidates and the June 2008 acquisition of Innovive Pharmaceuticals with four clinical stage oncology products including one that is currently in a pivotal clinical trial• Responsible for strategic realignment of company assets, focusing internal resources away from RNAi therapeutics to oral drugs for chaperone amplification and inhibition• In charge of preclinical, manufacturing, regulatory, and clinical development of the drug arimoclomol for the treatment of ALS, including planning and successful completion of five Phase I studies, a Phase IIa, and Phase IIa open-label extension. • Responsible for preclinical development and IND preparation for a planned phase IIa clinical trial for diabetic foot ulcers with the drug candidate iroxanadine.

San Diego, California

As an officer of the company and its third employee, I was a major contributor to building the company and increasing its (private) capitalization by over 50-fold. CHIEF TECHNICAL OFFICER & VICE PRESIDENT R&D (2001-2003) • Established two R&D facilities and led a multi-functional department of up to 70 people and seamlessly integrated multiple drug target discovery and validation programs (cancer, viral, neurodegenerative disease, and obesity/diabetes) and therapeutic programs (cardiovascular, skin, and eye disease) into a cohesive strategic matrix• Responsible for establishing and maintaining drug discovery alliances with Novartis ($150M), Pfizer ($50M), Chugai, and Medarex• Invented and implemented the Company’s platform technology “Inverse Genomics” • Successfully expanded the company intellectual property portfolio, and met milestones for corporate partnerships, resulting in contract extensions. Established Company’s IP strategy with involvement throughout the process from writing to issuance• Responsible for pre-clinical drug evaluation supporting the Clinical Affairs department with IND preparation for a Phase II clinical trial for Proliferative Vitreoretinopathy, and a phase Ib clinical trial for hypertrophic scarring. Previously directly responsible for Regulatory Affairs, preparing, submitting, and supporting the Company’s lead IND application for gene therapy of AIDS, resulting in a Phase Ib clinical trial• Responsible for GMP drug manufacturing, certified "Pharmacy Exempt" by the California State Board of Pharmacy, required for state-approved GMP drug manufacturing• Established and directed the QA/QC department, leading to issuance of the company’s Investigational Drug Manufacturing License by the State of California (License # 41658, 1997-2000)• Financed operations through competitive grants, awarded over $4M from the NIH and DOE

La Jolla

As one of the company’s first principle scientists, helped establish the world’s first gene therapy company and position it for acquisition by Chiron.ASSOCIATE DIRECTOR, ONCOLOGY • Managed a pre-clinical staff of six people, while in charge of the inter-departmental project team responsible for the clinical development of the company’s lead cancer immunotherapeutic program that established the corporate alliance with, and ultimately the acquisition by, Chiron • Conceived, initiated, directed, and patented several immunotherapeutic approaches to cancer treatment (melanoma, breast, and colon), from initial proof-of-concept feasibility studies through to writing the Investigator Brochure, Pharmacology, and Chemistry, Manufacturing, and Control sections of the INDs, leading to the initiation of two published Phase Ib clinical trials for cancer immunotherapy • Generation and molecular and cellular characterization of product manufacturing cell lines for Master File submission• Managed a staff of 8, responsible for product development of the Company’s lead immunotherapeutic drug candidate used in several published AIDS clinical trials• Initiated and directed a multidisciplinary assay development group that developed and validated assays for QA/QC product release testing• Supervised a group of 3 people, establishing the therapeutic potential of regulated expression of conditionally lethal genes using tissue-specific transcriptional promoters for AIDS and cancer, ultimately resulting in issued patents and a published cancer clinical trial

La Jolla

Post-doctoral fellow conducting independent research on the role of oncoprotein phosphorylation in controlling tumorigenesis and gene expression using protein chemistry, molecular biology, site-directed mutagenesis, and gene transfer

Ph.D., Biochemistry

UCLA, Los Angeles, CA Department of Chemistry and Biochemistry Departmental Research Scholar Award National Research Service Award Thesis.

Bachelor Of Science (B.S.), Biochemistry

UCLA, Los Angeles, CA Department of Chemistry Cum Laude with Departmental Honors Honors Research in Enzymology Thesis: Purification.